[go: up one dir, main page]

NO20070510L - Fremgangsmater og reagenser for behandling av metabole forstyrrelser - Google Patents

Fremgangsmater og reagenser for behandling av metabole forstyrrelser

Info

Publication number
NO20070510L
NO20070510L NO20070510A NO20070510A NO20070510L NO 20070510 L NO20070510 L NO 20070510L NO 20070510 A NO20070510 A NO 20070510A NO 20070510 A NO20070510 A NO 20070510A NO 20070510 L NO20070510 L NO 20070510L
Authority
NO
Norway
Prior art keywords
treatment
methods
metabolic disorders
reagents
compositions
Prior art date
Application number
NO20070510A
Other languages
English (en)
Inventor
Margaret S Lee
Grant R Zimmermann
Daniel Grau
Curtis Keith
M James Nichols
Alyce Lynn Finelli
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35783202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070510(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20070510L publication Critical patent/NO20070510L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Oppfinnelsen angår sammensetninger, fremgangsmåter og kit for behandling av metabolske forstyrrelser slik som diabetes og overvekt. Sammensetningene omfatter en kombinasjon av bezafibrat og diflunisal, eller analoger derav.
NO20070510A 2004-06-30 2007-01-26 Fremgangsmater og reagenser for behandling av metabole forstyrrelser NO20070510L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58438004P 2004-06-30 2004-06-30
US64932905P 2005-02-02 2005-02-02
PCT/US2005/023030 WO2006004803A1 (en) 2004-06-30 2005-06-29 Methods and reagents for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
NO20070510L true NO20070510L (no) 2007-03-29

Family

ID=35783202

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070510A NO20070510L (no) 2004-06-30 2007-01-26 Fremgangsmater og reagenser for behandling av metabole forstyrrelser

Country Status (14)

Country Link
US (1) US7795310B2 (no)
EP (1) EP1781303A4 (no)
JP (1) JP2008505176A (no)
KR (1) KR20070027747A (no)
AR (1) AR049955A1 (no)
AU (1) AU2005259864A1 (no)
BR (1) BRPI0512856A (no)
CA (1) CA2571683A1 (no)
IL (1) IL180251A0 (no)
MX (1) MX2007000142A (no)
NO (1) NO20070510L (no)
RU (1) RU2007103178A (no)
TW (1) TW200608961A (no)
WO (1) WO2006004803A1 (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
NZ549721A (en) 2004-03-05 2010-08-27 Univ Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
JP2007532655A (ja) * 2004-04-14 2007-11-15 ワイス ラパマイシンコンジュゲートおよび抗体のための前駆体である、ジカルボン酸とのラパマイシン４２−エステルおよびジカルボン酸とのｆｋ−５０６３２−エステルの調製プロセス
JP2009511634A (ja) * 2005-10-18 2009-03-19 エージェリオン ファーマシューティカルズ 哺乳動物において高脂血症に関連する障害を治療する方法
FR2904935A1 (fr) * 2006-08-18 2008-02-22 Centre Nat Rech Scient Composition antidiabetique apte a stimuler la secretion d'insuline et destinee au traitement du diabete de type 2 (diabete non insulino-dependant).
JP2010513534A (ja) * 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ， インコーポレイテッド Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
KR101460820B1 (ko) * 2007-01-16 2014-11-11 아이피아이엔티엘, 엘엘씨 대사 증후군의 치료를 위한 신규한 조성물
WO2008091338A1 (en) * 2007-01-23 2008-07-31 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
WO2008138123A1 (en) * 2007-05-09 2008-11-20 Thomas David Y Screening assay to identify correctors of protein trafficking defects
WO2009052376A1 (en) 2007-10-18 2009-04-23 Musc Foundation For Research Development Methods for the diagnosis of genitourinary cancer
US8168391B2 (en) * 2007-11-07 2012-05-01 Burnham Institute For Medical Research Method for modulating insulin production
EP2291182A1 (en) * 2008-05-13 2011-03-09 Genmedica Therapeutics SL Salicylate conjugates useful for treating metabolic disorders
CA2666036C (en) * 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
CN102239149B (zh) * 2008-10-06 2015-05-13 约翰·霍普金斯大学 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
JP2012520342A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
CA2755072A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination therapies for treating metabolic disorders
WO2010107702A1 (en) * 2009-03-16 2010-09-23 Ipintl, Llc Treating alzheimer's disease and osteoporosis and reducing aging
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
EP2521719B1 (en) 2010-01-08 2015-07-29 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
US20130210821A1 (en) * 2010-05-27 2013-08-15 James E. Vath Methods for Treating Obesity
CA2806221A1 (en) 2010-07-22 2012-01-26 Zafgen, Inc. Tricyclic compounds and methods of making and using same
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン，インコーポレイテッド ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
EP2668169B1 (en) 2011-01-26 2017-11-15 Zafgen, Inc. Tetrazole compounds and methods of making and using same
US20140050728A1 (en) * 2011-01-28 2014-02-20 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
CN103534244B (zh) 2011-03-08 2016-10-12 扎夫根股份有限公司 氧杂螺[2.5]辛烷衍生物及类似物
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
EP2705030B1 (en) 2011-05-06 2016-07-27 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
MX343687B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
KR101350824B1 (ko) * 2011-12-14 2014-01-13 서울대학교산학협력단 리파아제 특이적 지질-펩타이드 기질 라이브러리 및 이를 이용한 리파아제 저해제를 유효성분으로 함유하는 비만 및 지질대사 이상 관련 질환의 치료 및 예방용 약학적 조성물
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
WO2013109735A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US20150045610A1 (en) * 2012-04-12 2015-02-12 Monell Chemical Senses Center Method of modifying spermatogenesis, spermiogenesis and/or fertility in mammals
EP2846792B1 (en) 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
CA2873574A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
AU2013337287B2 (en) 2012-11-05 2017-03-23 Zafgen, Inc. Methods of treating liver diseases
US10174009B2 (en) 2012-11-05 2019-01-08 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
WO2014084421A1 (en) * 2012-11-29 2014-06-05 Mediplex Corp. Bile acid oligomer conjugate for novel vesicular transport and use thereof
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
NZ741985A (en) 2013-03-14 2019-12-20 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
MX362391B (es) 2013-03-14 2019-01-15 Zafgen Inc Métodos de tratamiento de enfermedad renal y otros trastornos.
US20140275138A1 (en) * 2013-03-15 2014-09-18 Cba Pharma, Inc. Method and products for treating diabetes
CA2917780C (en) * 2013-07-25 2023-01-24 Medicinova, Inc. Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels
JP6560200B2 (ja) 2013-10-17 2019-08-14 ザ ジェネラル ホスピタル コーポレイション 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
WO2015120065A1 (en) * 2014-02-05 2015-08-13 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
WO2017059132A1 (en) * 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
EP3426239A1 (en) * 2016-03-07 2019-01-16 Atrogi AB Compounds for the treatment of hyperglycaemia
WO2018204829A1 (en) * 2017-05-04 2018-11-08 University Of Maryland, Baltimore Methods for preventing neural tube defects in diabetic pregnancy
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
US20210290580A1 (en) * 2018-07-31 2021-09-23 Wen Tan New use of carbamate ß phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects
CN109157537B (zh) * 2018-08-31 2021-02-19 中国科学院深圳先进技术研究院 葫芦素e在制备治疗血管新生不足相关疾病药物或生物医用材料中的用途和应用其的产品
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
CN109913522A (zh) * 2019-04-03 2019-06-21 五邑大学 茶多肽在制备改善、缓解或治疗痛风药物中的应用
EP4149962A4 (en) * 2020-05-11 2024-06-19 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing brown adipogenesis
US20230285376A1 (en) 2020-07-29 2023-09-14 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
AU2022276512A1 (en) * 2021-05-20 2023-11-30 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing brown adipogenesis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
JP2002528495A (ja) * 1998-10-30 2002-09-03 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化された非ステロイド抗炎症性化合物、組成物および使用方法
ATE289586T1 (de) * 1999-03-01 2005-03-15 Pfizer Prod Inc Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
AU2001253618A1 (en) * 2000-04-21 2001-11-07 Arch Development Corporation Flavopiridol drug combinations and methods with reduced side effects
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US7811593B2 (en) * 2002-03-25 2010-10-12 Jian Luo Pharmaceutical composition with combined active agents and methods for using the same
JP2006512334A (ja) * 2002-12-10 2006-04-13 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤とｐｐａｒ−アルファ化合物の組み合わせ
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity

Also Published As

Publication number Publication date
TW200608961A (en) 2006-03-16
EP1781303A4 (en) 2008-07-02
RU2007103178A (ru) 2008-08-10
US7795310B2 (en) 2010-09-14
AU2005259864A1 (en) 2006-01-12
AR049955A1 (es) 2006-09-20
EP1781303A1 (en) 2007-05-09
IL180251A0 (en) 2007-09-20
CA2571683A1 (en) 2006-01-12
JP2008505176A (ja) 2008-02-21
MX2007000142A (es) 2007-03-26
WO2006004803A1 (en) 2006-01-12
KR20070027747A (ko) 2007-03-09
US20060069161A1 (en) 2006-03-30
BRPI0512856A (pt) 2008-04-08

Similar Documents

Publication Publication Date Title
NO20070510L (no) Fremgangsmater og reagenser for behandling av metabole forstyrrelser
DK1599468T3 (da) 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
NO20092034L (no) Kjemiske forbindelser og anvendelser
DK1606282T3 (da) Phenyl- og pyridylpipereidinye-derivater som modulatorer af glucosemetabolisme
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
EA200600235A1 (ru) Трёхзамещённые производные арилов и гетероарилов в качестве модуляторов метаболизма и профилактика и лечение связанных с ними нарушений
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
BRPI0606228A2 (pt) inibidores de enzima 11-beta-hidroxiesteróide desidrogenase tipo 1
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
BRPI0508098A (pt) compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
EA201070039A1 (ru) Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
NO20075647L (no) Kjemiske forbindelser
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
DK1592786T3 (da) Diagnosticering og behandling af multipel sulfatase-defekt og andet ved anvendelse af et formylglycin-dannende enzym (FGE).
NO20075821L (no) Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner
NO20090596L (no) Antivirale fosfinatforbindelser
NO20092021L (no) Faste former inneholdende 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluor-fenylamino)-9H-purin-2-ylamino]-cykloheksan-1-ol, sammensetninger derav og anvendelse derav
WO2007022518A8 (en) New uses of glucoregulatory proteins
NO20080462L (no) Krystallformer av astaxantin
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO20072290L (no) Organiske forbindelser.
EA200701742A1 (ru) Способы получения сиропа

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application